At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed stage IV breast cancer
- ✓HER2-positive by FISH or immunohistochemistry 3+ staining
- ✓Female, age 18 and over
- ✓Zubrod performance status 0-2
- ✕No primary or metastatic brain or CNS tumors
- ✕Effusions or ascites as only sites of disease
- ✕Prior docetaxel or vinorelbine
- ✕More than 1 prior adjuvant or neoadjuvant chemotherapy regimen
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer
In Brief
A Phase 2 clinical trial evaluating filgrastim, trastuzumab, and 2 other interventions for Breast Cancer. Completed, enrolled 76 participants across 145 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors, such as filgrastim, may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with docetaxel, vinorelbine, and filgrastim in treating women who have stage IV breast cancer.